NO851160L - Fremgangsmaate for fremstilling av cyklosporiner - Google Patents

Fremgangsmaate for fremstilling av cyklosporiner

Info

Publication number: NO851160L
Authority: NO; Norway
Prior art keywords: nva; cyclosporine; val; mebmt; ser
Prior art date: 1984-03-23

Application number

NO851160A

Other languages

English (en)

Norwegian (no)

Inventor

Roland Wenger

Rene P Traber

Hans Kobel

Hans Hofmann

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-23

Filing date

1985-03-22

Publication date

1985-09-24

1984-03-23 Priority claimed from GB848407618A external-priority patent/GB8407618D0/en

1984-05-10 Priority claimed from GB848411922A external-priority patent/GB8411922D0/en

1985-03-22 Application filed by Sandoz Ag filed Critical Sandoz Ag

1985-09-24 Publication of NO851160L publication Critical patent/NO851160L/no

Links

229930182912 cyclosporin Natural products 0.000 title claims description 113
238000000034 method Methods 0.000 title claims description 35
238000002360 preparation method Methods 0.000 title claims description 9
108010036941 Cyclosporins Proteins 0.000 title description 52
229960001265 ciclosporin Drugs 0.000 claims description 136
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 72
108010036949 Cyclosporine Proteins 0.000 claims description 70
229930105110 Cyclosporin A Natural products 0.000 claims description 29
125000000539 amino acid group Chemical group 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
235000015097 nutrients Nutrition 0.000 claims description 7
230000002538 fungal effect Effects 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 3
229930195711 D-Serine Natural products 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
239000012531 culture fluid Substances 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 58
SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 40
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 21
239000003480 eluent Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
238000012360 testing method Methods 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
238000011282 treatment Methods 0.000 description 14
239000000203 mixture Substances 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
239000000284 extract Substances 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
206010003246 arthritis Diseases 0.000 description 6
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
238000000605 extraction Methods 0.000 description 6
230000001506 immunosuppresive effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
238000010898 silica gel chromatography Methods 0.000 description 6
239000007858 starting material Substances 0.000 description 6
230000003110 anti-inflammatory effect Effects 0.000 description 5
238000000855 fermentation Methods 0.000 description 5
230000004151 fermentation Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
230000002141 anti-parasite Effects 0.000 description 4
230000004968 inflammatory condition Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000013587 production medium Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
208000030852 Parasitic disease Diseases 0.000 description 3
239000008272 agar Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000011097 chromatography purification Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000007429 general method Methods 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000000401 methanolic extract Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000000967 suction filtration Methods 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
241001149960 Tolypocladium inflatum Species 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000010643 digestive system disease Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000018685 gastrointestinal system disease Diseases 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
229940100688 oral solution Drugs 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
201000006353 Filariasis Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
208000000291 Nematode infections Diseases 0.000 description 1
241000364057 Peoria Species 0.000 description 1
241000224017 Plasmodium berghei Species 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000004938 Trematode Infections Diseases 0.000 description 1
241000869417 Trematodes Species 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
-1 benzyl halide Chemical class 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000012364 cultivation method Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
238000013059 nephrectomy Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000004088 simulation Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003760 tallow Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000001239 threonyl group Chemical group 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/19—Antibiotic
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO851160A 1984-03-23 1985-03-22 Fremgangsmaate for fremstilling av cyklosporiner NO851160L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB848407618A GB8407618D0 (en)	1984-03-23	1984-03-23	Organic compounds
GB848411922A GB8411922D0 (en)	1984-05-10	1984-05-10	Organic compounds

Publications (1)

Publication Number	Publication Date
NO851160L true NO851160L (no)	1985-09-24

Family

ID=26287502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO851160A NO851160L (no)	1984-03-23	1985-03-22	Fremgangsmaate for fremstilling av cyklosporiner

Country Status (24)

Country	Link
US (1)	US4639434A (fr)
JP (1)	JPH08838B2 (fr)
AT (1)	AT388737B (fr)
BE (1)	BE901980A (fr)
CA (1)	CA1247546A (fr)
CH (1)	CH667274A5 (fr)
CS (1)	CS249542B2 (fr)
DE (1)	DE3509809A1 (fr)
DK (1)	DK128285A (fr)
ES (1)	ES8702926A1 (fr)
FI (1)	FI851120L (fr)
FR (1)	FR2561651B1 (fr)
GB (1)	GB2155936B (fr)
GR (1)	GR850716B (fr)
HU (1)	HU200786B (fr)
IL (1)	IL74681A (fr)
IT (1)	IT1199962B (fr)
LU (1)	LU85819A1 (fr)
NL (1)	NL8500828A (fr)
NO (1)	NO851160L (fr)
NZ (1)	NZ211526A (fr)
PH (2)	PH21868A (fr)
PT (1)	PT80149B (fr)
SE (1)	SE461334B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3587342T2 (de)	1984-10-04	1993-12-02	Sandoz Ag	Cyclosporine.
US4798823A (en) *	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
EP0296122B1 (fr) *	1987-06-17	1993-09-29	Sandoz Ag	Cycloporines et leur emploi comme médicaments
DE3888357T2 (de) *	1987-06-22	1994-09-15	Merck & Co Inc	Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
US5227467A (en) *	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US4839342A (en) *	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
DE3851152T2 (de) *	1987-09-03	1995-01-26	Univ Georgia	Cyclosporin-augenmittel.
US5089390A (en) *	1987-09-04	1992-02-18	Syntex (U.S.A.) Inc.	2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US5236899A (en) *	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) *	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
CH679119A5 (fr) *	1988-05-13	1991-12-31	Sandoz Ag
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US5122511A (en) *	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5202310A (en) *	1990-06-06	1993-04-13	Levy Gary A	Cyclosporine metabolites
SK278808B6 (sk) *	1990-11-02	1998-03-04	Novartis Ag	Cyklosporíny, ich použitie pri príprave liečiva na
DE69133095T2 (de)	1990-11-20	2003-03-27	Dade Behring Marburg Gmbh	Cyclosporin-Immunoassay
US5747330A (en) *	1996-06-05	1998-05-05	Poli Industria Chimica	Antibiotic producing microbe
DE69832984T2 (de)	1997-10-08	2006-09-21	Isotechnika, Inc., Edmonton	DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US5990274A (en) *	1997-11-25	1999-11-23	Dade Behring Inc.	Cyclosporine derivatives and uses thereof
US7449544B2 (en) *	1999-11-30	2008-11-11	Cyclacel Limited	p21 peptides
PL210795B1 (pl) *	2001-10-19	2012-03-30	Isotechnika Inc	Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247
NZ531946A (en) *	2001-10-19	2005-09-30	Isotechnika Inc	Preconcentrate formulations comprising cyclosporin analogue microemulsions that reduce adverse effects while maintaining high bioavailability
AU2004222306A1 (en) *	2003-03-17	2004-09-30	Albany Molecular Research, Inc.	Novel cyclosporins
JP2008514701A (ja) *	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2008514702A (ja) *	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	新規シクロスポリン類似体およびそれらの薬学的使用
WO2006041631A2 (fr) *	2004-10-06	2006-04-20	Amr Technology, Inc.	Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7576057B2 (en)	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
SG191069A1 (en)	2010-12-15	2013-07-31	Isotechnika Pharma Inc	Cyclosporine analogue molecules modified at amino acid 1 and 3
CA2852056C (fr)	2011-03-11	2021-08-10	Beth Israel Deaconess Medical Center, Inc.	Anticorps anti-cd40 et leurs utilisations
CN104877013B (zh) *	2015-06-03	2018-04-20	兰州大学	环孢菌素t及其制备方法和应用
CN116063481A (zh)	2015-09-04	2023-05-05	普里玛托普医疗股份有限公司	人源化抗-cd40抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0056782B1 (fr) *	1981-01-09	1984-08-01	Sandoz Ag	Cyclosporines
JPS57140753A (en) *	1981-01-09	1982-08-31	Sandoz Ag	Novel cyclosporine

1985
- 1985-03-18 CH CH1194/85A patent/CH667274A5/de not_active IP Right Cessation
- 1985-03-19 DE DE19853509809 patent/DE3509809A1/de not_active Ceased
- 1985-03-19 US US06/713,429 patent/US4639434A/en not_active Expired - Fee Related
- 1985-03-19 FR FR858504172A patent/FR2561651B1/fr not_active Expired - Lifetime
- 1985-03-20 PH PH32013A patent/PH21868A/en unknown
- 1985-03-20 GB GB08507270A patent/GB2155936B/en not_active Expired
- 1985-03-20 PH PH32014A patent/PH23357A/en unknown
- 1985-03-20 FI FI851120A patent/FI851120L/fi not_active Application Discontinuation
- 1985-03-21 NZ NZ211526A patent/NZ211526A/xx unknown
- 1985-03-21 LU LU85819A patent/LU85819A1/fr unknown
- 1985-03-21 DK DK128285A patent/DK128285A/da not_active Application Discontinuation
- 1985-03-21 GR GR850716A patent/GR850716B/el unknown
- 1985-03-21 HU HU851045A patent/HU200786B/hu not_active IP Right Cessation
- 1985-03-21 BE BE1/011217A patent/BE901980A/fr not_active IP Right Cessation
- 1985-03-21 ES ES541465A patent/ES8702926A1/es not_active Expired
- 1985-03-21 IL IL74681A patent/IL74681A/xx unknown
- 1985-03-21 SE SE8501392A patent/SE461334B/sv not_active IP Right Cessation
- 1985-03-21 CA CA000477127A patent/CA1247546A/fr not_active Expired
- 1985-03-21 PT PT80149A patent/PT80149B/pt not_active IP Right Cessation
- 1985-03-21 NL NL8500828A patent/NL8500828A/nl not_active Application Discontinuation
- 1985-03-22 NO NO851160A patent/NO851160L/no unknown
- 1985-03-22 IT IT47852/85A patent/IT1199962B/it active
- 1985-03-22 AT AT0086385A patent/AT388737B/de not_active IP Right Cessation
- 1985-03-22 JP JP60059339A patent/JPH08838B2/ja not_active Expired - Lifetime
- 1985-03-23 CS CS852132A patent/CS249542B2/cs unknown

Also Published As

Publication number	Publication date
FR2561651B1 (fr)	1990-03-09
IT8547852A0 (it)	1985-03-22
PT80149A (en)	1985-04-01
IL74681A (en)	1989-09-10
IL74681A0 (en)	1985-06-30
AT388737B (de)	1989-08-25
PH21868A (en)	1988-03-25
JPH08838B2 (ja)	1996-01-10
DK128285A (da)	1985-09-24
GB2155936A (en)	1985-10-02
DK128285D0 (da)	1985-03-21
JPS60215700A (ja)	1985-10-29
FR2561651A1 (fr)	1985-09-27
CH667274A5 (de)	1988-09-30
GB2155936B (en)	1987-09-16
IT1199962B (it)	1989-01-05
NZ211526A (en)	1988-08-30
US4639434A (en)	1987-01-27
FI851120A0 (fi)	1985-03-20
HU200786B (en)	1990-08-28
SE461334B (sv)	1990-02-05
ATA86385A (de)	1989-01-15
CA1247546A (fr)	1988-12-28
FI851120L (fi)	1985-09-24
IT8547852A1 (it)	1986-09-22
ES8702926A1 (es)	1987-01-16
SE8501392D0 (sv)	1985-03-21
GR850716B (fr)	1985-07-19
DE3509809A1 (de)	1986-01-09
HUT38370A (en)	1986-05-28
GB8507270D0 (en)	1985-04-24
ES541465A0 (es)	1987-01-16
LU85819A1 (fr)	1985-12-12
CS249542B2 (en)	1987-03-12
BE901980A (fr)	1985-09-23
SE8501392L (sv)	1985-09-24
PT80149B (en)	1987-03-23
NL8500828A (nl)	1985-10-16
PH23357A (en)	1989-07-14

Publication	Publication Date	Title
NO851160L (no)	1985-09-24	Fremgangsmaate for fremstilling av cyklosporiner
US4764503A (en)	1988-08-16	Novel cyclosporins
US6255100B1 (en)	2001-07-03	Cyclosporin fermentation process
EP0056782B1 (fr)	1984-08-01	Cyclosporines
US4914188A (en)	1990-04-03	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US6809077B2 (en)	2004-10-26	Cyclosporin analogs for the treatment of autoimmune diseases
US6979671B2 (en)	2005-12-27	Cyclosporins for the treatment of immune disorders
von Wartburg et al.	1988	1 cyclosporins, fungal metabolites with immunosuppressive activities
EP0373260B1 (fr)	1994-03-09	Dérivés de cyclosporine avec un acide aminé modifié en position 8
DE69028967T2 (de)	1997-05-15	Cyclosporin- Derivate
GB2207678A (en)	1989-02-08	Novel immunosuppressive fluorinated cyclosporin analogs
AU596071B2 (en)	1990-04-26	Novel cyclosporins
JPH0338280B2 (fr)	1991-06-10
NO310028B1 (no)	2001-05-07	Cyklosporiner, deres anvendelse og fremstilling samt en biologisk ren kilde
JPH06256261A (ja)	1994-09-13	エンドセリン−１拮抗物質
RO110144B1 (ro)	1995-10-30	Noi ciclosporine, procedeu de sinteză a acestora și metodă de tratament și prevenire a SIDA